The abnormalities in blood coagulation in patients with diabetes can lead to a prothrombotic state and requirement for the administration of direct anticoagulants. However, no comparative studies have been conducted on the effects of different direct anticoagulants. A head-to-head investigation of the impact of anticoagulants in 50 patients of type 1 diabetes mellitus (DMT1) was performed, and the data were compared to 50 generally healthy individuals. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were measured in plasma treated with vehicle, heparin, or four direct anticoagulants at 1 μM. In addition to common biochemical parameters, novel inflammatory markers (neopterin, kynurenine/tryptophan ratio) and major vitamin K forms were measured. Heparin and dabigatran treatments resulted in prolonged coagulation in DMT1 patients compared to healthy individuals in both tests (both p < 0.001). The same phenomenon was observed for rivaroxaban and apixaban-treated samples in PT (p < 0.001). Interestingly, healthy volunteers had higher total vitamin K levels than DMT1. Further analysis suggested that observed coagulation differences were not caused by differences in glycemia but were rather associated with an unexpected, better lipid profile of our DMT1 group. There were also correlations between prolongation of coagulation brought about by the most active anticoagulants and inflammatory markers, and hence inflammatory state probably also contributed to the differences, as well as the mentioned differences in vitamin K levels. Conclusively, this paper suggests the suitability for controlling the effects of direct anticoagulants in DMT1 patients.

3rd Department of Internal Medicine Metabolic Care and Gerontology University Hospital and Faculty of Medicine in Hradec Králové Charles University Hradec Králové Czech Republic

Department of Analytical Chemistry Faculty of Pharmacy in Hradec Králové Charles University Hradec Králové Czech Republic

Department of Clinical Biochemistry and Diagnostics University Hospital Hradec Králové Czech Republic

Department of Military Internal Medicine and Military Hygiene Military Faculty of Medicine University of Defence Hradec Králové Czech Republic

Department of Pharmacology and Toxicology Faculty of Pharmacy in Hradec Králové Charles University Hradec Králové Czech Republic

Zobrazit více v PubMed

Versteeg HH, Heemskerk JWM, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev. 2013;93(1):327–58. doi: 10.1152/physrev.00016.2011 PubMed DOI

De Pablo-Moreno JA, Serrano LJ, Revuelta L, Sánchez MJ, Liras A. The vascular endothelium and coagulation: homeostasis, disease, and treatment, with a focus on the Von Willebrand factor and factors VIII and V. Int J Mol Sci. 2022;23(15):8283. doi: 10.3390/ijms23158283 PubMed DOI PMC

Achneck HE, Sileshi B, Parikh A, Milano CA, Welsby IJ, Lawson JH. Pathophysiology of bleeding and clotting in the cardiac surgery patient: from vascular endothelium to circulatory assist device surface. Circulation. 2010;122(20):2068–77. doi: 10.1161/CIRCULATIONAHA.110.936773 PubMed DOI

Lemkes BA, Hermanides J, Devries JH, Holleman F, Meijers JCM, Hoekstra JBL. Hyperglycemia: a prothrombotic factor?. J Thromb Haemost. 2010;8(8):1663–9. doi: 10.1111/j.1538-7836.2010.03910.x PubMed DOI

Vazzana N, Ranalli P, Cuccurullo C, Davì G. Diabetes mellitus and thrombosis. Thromb Res. 2012;129(3):371–7. doi: 10.1016/j.thromres.2011.11.052 PubMed DOI

Sobczak AIS, Stewart AJ. Coagulatory defects in Type-1 and Type-2 diabetes. Int J Mol Sci. 2019;20(24):6345. doi: 10.3390/ijms20246345 PubMed DOI PMC

Klem I, Wehinger C, Schneider B, Hartl E, Finsterer J, Stöllberger C. Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10-year follow-up. Diabetes Metab Res Rev. 2003;19(4):320–8. doi: 10.1002/dmrr.386 PubMed DOI

Movahed M-R, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol. 2005;105(3):315–8. doi: 10.1016/j.ijcard.2005.02.050 PubMed DOI

Newman JD, Schwartzbard AZ, Weintraub HS, Goldberg IJ, Berger JS. Primary prevention of cardiovascular disease in diabetes mellitus. J Am Coll Cardiol. 2017;70(7):883–93. doi: 10.1016/j.jacc.2017.07.001 PubMed DOI PMC

Pomero F, Dentali F, Mumoli N, Salomone P, Tangianu F, Desideri G, et al. The continuous challenge of antithrombotic strategies in diabetes: focus on direct oral anticoagulants. Acta Diabetol. 2019;56(12):1247–58. doi: 10.1007/s00592-019-01426-2 PubMed DOI

Zhang Y, He L, Chen H, Lu S, Xiong Y, Liu J, et al. Manifestations of blood coagulation and its relation to clinical outcomes in severe COVID-19 patients: Retrospective analysis. Int J Lab Hematol. 2020;42(6):766–72. doi: 10.1111/ijlh.13273 PubMed DOI PMC

Bulani Y, Srinivasan K, Sharma SS. Attenuation of type-1 diabetes-induced cardiovascular dysfunctions by direct thrombin inhibitor in rats: a mechanistic study. Mol Cell Biochem. 2019;451(1–2):69–78. doi: 10.1007/s11010-018-3394-9 PubMed DOI

Dorgalaleh A, Favaloro EJ, Bahraini M, Rad F. Standardization of Prothrombin Time/International Normalized Ratio (PT/INR). Int J Lab Hematol. 2021;43(1):21–8. doi: 10.1111/ijlh.13349 PubMed DOI

Meijer P, Kynde K, van den Besselaar AMHP, Van Blerk M, Woods TAL. International normalized ratio (INR) testing in Europe: between-laboratory comparability of test results obtained by quick and owren reagents. Clin Chem Lab Med. 2018;56(10):1698–703. doi: 10.1515/cclm-2017-0976 PubMed DOI

Mladěnka P, Macáková K, Kujovská Krčmová L, Javorská L, Mrštná K, Carazo A, et al. Vitamin K - sources, physiological role, kinetics, deficiency, detection, therapeutic use, and toxicity. Nutr Rev. 2022;80(4):677–98. doi: 10.1093/nutrit/nuab061 PubMed DOI PMC

Winter WE, Flax SD, Harris NS. Coagulation testing in the core laboratory. Lab Med. 2017;48(4):295–313. doi: 10.1093/labmed/lmx050 PubMed DOI

Liu L, Ying M, Chen S, Li Q, Chen G, Li H, et al. The association between prothrombin time-international normalized ratio and long-term mortality in patients with coronary artery disease: a large cohort retrospective study with 44,662 patients. BMC Cardiovasc Disord. 2022;22(1):297. doi: 10.1186/s12872-022-02619-4 PubMed DOI PMC

Oldgren J, Linder R, Grip L, Siegbahn A, Wallentin L. Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease. Eur Heart J. 1999;20(22):1657–66. doi: 10.1053/euhj.1999.1750 PubMed DOI

Keyl C, Zimmer E, Bek MJ, Wiessner M, Trenk D. Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia. Thromb Haemost. 2016;115(6):1081–9. doi: 10.1160/TH15-11-0847 PubMed DOI

Dunois C. Laboratory Monitoring of Direct Oral Anticoagulants (DOACs). Biomedicines. 2021;9(5):445. doi: 10.3390/biomedicines9050445 PubMed DOI PMC

Bavalia R, Veenhuizen JE, Hengeveld RCC, Braeken D, Gulpen AJW, Ten Cate H, et al. Direct oral anticoagulant blood level monitoring in daily practice. Thrombosis Update. 2021;3:100049. doi: 10.1016/j.tru.2021.100049 DOI

ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Addendum. 2. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes care 2023;46(Suppl. 1):S19-S40. Diabetes Care. 2023;46(9):1715. doi: 10.2337/dc23-ad08 PubMed DOI PMC

Carazo A, Hrubša M, Konečný L, Skořepa P, Paclíková M, Musil F, et al. Sex-related differences in platelet aggregation: a literature review supplemented with local data from a group of generally healthy individuals. Semin Thromb Hemost. 2023;49(5):488–506. doi: 10.1055/s-0042-1756703 PubMed DOI

Krcmova L, Solichova D, Melichar B, Kasparova M, Plisek J, Sobotka L, et al. Determination of neopterin, kynurenine, tryptophan and creatinine in human serum by high throuput HPLC. Talanta. 2011;85(3):1466–71. doi: 10.1016/j.talanta.2011.06.027 PubMed DOI

Mrštná K, Matoušová K, Krčmová LK, Carazo A, Pourová J, Mladěnka P, et al. Analysis of vitamin K1 and major K2 variants in rat/human serum and lipoprotein fractions by a rapid, simple, and sensitive UHPLC-MS/MS method. J Chromatogr A. 2024;1714:464548. doi: 10.1016/j.chroma.2023.464548 PubMed DOI

Cermanová M, Melichar B, Solichová D, Bláha M, Bláha V, Blazek M, et al. Urinary neopterin and microalbuminuria in patients treated by low-density lipoprotein apheresis. Pteridines. 2005;16(4):174–83. doi: 10.1515/pteridines.2005.16.4.174 DOI

Dublin S, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL, et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med. 2010;25(8):853–8. doi: 10.1007/s11606-010-1340-y PubMed DOI PMC

Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62. doi: 10.1016/S0140-6736(13)62343-0 PubMed DOI

Stegenga ME, van der Crabben SN, Blümer RME, Levi M, Meijers JCM, Serlie MJ, et al. Hyperglycemia enhances coagulation and reduces neutrophil degranulation, whereas hyperinsulinemia inhibits fibrinolysis during human endotoxemia. Blood. 2008;112(1):82–9. doi: 10.1182/blood-2007-11-121723 PubMed DOI PMC

Boden G, Rao AK. Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. Curr Diab Rep. 2007;7(3):223–7. doi: 10.1007/s11892-007-0035-1 PubMed DOI

Zhao Y, Zhang J, Zhang J, Wu J. Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen values. PLoS One. 2011;6(1):e16470. doi: 10.1371/journal.pone.0016470 PubMed DOI PMC

Ambelu YA, Shiferaw MB, Abebe M, Enawgaw B. Prothrombin time, activated partial thromboplastin time and platelet counts of type II diabetes mellitus: a comparative study. J Diabetes Metab Disord. 2018;17(2):117–21. doi: 10.1007/s40200-018-0347-5 PubMed DOI PMC

Ebrahim H, Asrie F, Getaneh Z. Basic coagulation profiles and platelet parameters among adult Type 1 and Type 2 diabetes patients at dessie referral hospital, Northeast Ethiopia: comparative cross-sectional study. J Blood Med. 2021;12:33–42. doi: 10.2147/JBM.S287136 PubMed DOI PMC

Oyakhire F, Adejumo BIG, Aiyegbusi OV, Ogie EO, Egho EV, Ochannah PB, et al. Coagulation profile in diabetes mellitus and its association with microvascular complications in uncontrolled and controlled diabetes at edo specialist hospital, Benin-city, South-South, Nigeria. MedLabTechJ. 2023. doi: 10.31964/mltj.v8i2.493 DOI

Fadraersada J, Alva-Gallegos R, Skořepa P, Musil F, Javorská L, Matoušová K, et al. Head-to-head ex vivo comparison of clinically used direct anticoagulant drugs. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(6):4461–70. doi: 10.1007/s00210-023-02891-x PubMed DOI

Stegenga ME, van der Crabben SN, Levi M, de Vos AF, Tanck MW, Sauerwein HP, et al. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes. 2006;55(6):1807–12. doi: 10.2337/db05-1543 PubMed DOI

Shin H-J, Na H-S, Lee S, Lee G-W, Do S-H. The effect of hyperglycemia on blood coagulation: in vitro, observational healthy-volunteer study using rotational thromboelastography (ROTEM). Medicine (Baltimore). 2016;95(35):e4703. doi: 10.1097/MD.0000000000004703 PubMed DOI PMC

Zaccardi F, Rocca B, Rizzi A, Ciminello A, Teofili L, Ghirlanda G, et al. Platelet indices and glucose control in type 1 and type 2 diabetes mellitus: a case-control study. Nutr Metab Cardiovasc Dis. 2017;27(10):902–9. doi: 10.1016/j.numecd.2017.06.016 PubMed DOI

Abdool M, Kunutsor SK, Khunti K, Seidu S. Does the presence of diabetes mellitus confer an increased risk of stroke in patients with atrial fibrillation on direct oral anticoagulants? A systematic review and meta-analysis. Diabetes Metab Syndr. 2020;14(6):1725–33. doi: 10.1016/j.dsx.2020.08.038 PubMed DOI

Kim J-A, Kim J-E, Song SH, Kim HK. Influence of blood lipids on global coagulation test results. Ann Lab Med. 2015;35(1):15–21. doi: 10.3343/alm.2015.35.1.15 PubMed DOI PMC

Zwaal RF, Comfurius P, Bevers EM. Lipid-protein interactions in blood coagulation. Biochim Biophys Acta. 1998;1376(3):433–53. doi: 10.1016/s0304-4157(98)00018-5 PubMed DOI

Mutanen M, Freese R. Fats, lipids and blood coagulation. Curr Opin Lipidol. 2001;12(1):25–9. doi: 10.1097/00041433-200102000-00005 PubMed DOI

Lacombe J, Ferron M. Vitamin K-dependent carboxylation in β-cells and diabetes. Trends Endocrinol Metab. 2024;35(7):661–73. doi: 10.1016/j.tem.2024.02.006 PubMed DOI

Xie Y, Li S, Wu D, Wang Y, Chen J, Duan L, et al. Vitamin K: infection, inflammation, and auto-immunity. J Inflamm Res. 2024;17:1147–60. doi: 10.2147/JIR.S445806 PubMed DOI PMC

Qu B, Yan S, Ao Y, Chen X, Zheng X, Cui W. The relationship between vitamin K and T2DM: a systematic review and meta-analysis. Food Funct. 2023;14(19):8951–63. doi: 10.1039/d3fo02943c PubMed DOI

Bøgh Andersen I, Brasen CL, Nasimi H, Stougård M, Bliddal M, Green A, et al. Serum vitamin K1 associated to microangiopathy and/or macroangiopathy in individuals with and without diabetes. BMJ Open Diabetes Res Care. 2020;8(1):e000961. doi: 10.1136/bmjdrc-2019-000961 PubMed DOI PMC

Franchini M. Hemostasis and aging. Crit Rev Oncol Hematol. 2006;60(2):144–51. doi: 10.1016/j.critrevonc.2006.06.004 PubMed DOI

Wiebe N, Muntner P, Tonelli M. Associations of body mass index, fasting insulin, and inflammation with mortality: a prospective cohort study. Int J Obes (Lond). 2022;46(12):2107–13. doi: 10.1038/s41366-022-01211-2 PubMed DOI PMC

Avanzas P, Arroyo-Espliguero R, Kaski JC. Neopterin and cardiovascular disease: growing evidence for a role in patient risk stratification. Clin Chem. 2009;55(6):1056–7. doi: 10.1373/clinchem.2009.127084 PubMed DOI

Teunis CJ, Stroes ESG, Boekholdt SM, Wareham NJ, Murphy AJ, Nieuwdorp M, et al. Tryptophan metabolites and incident cardiovascular disease: the EPIC-Norfolk prospective population study. Atherosclerosis. 2023;387:117344. doi: 10.1016/j.atherosclerosis.2023.117344 PubMed DOI

Baumgartner R, Forteza MJ, Ketelhuth DFJ. The interplay between cytokines and the Kynurenine pathway in inflammation and atherosclerosis. Cytokine. 2019;122:154148. doi: 10.1016/j.cyto.2017.09.004 PubMed DOI

Huang M-J, Wei R-B, Wang Y, Su T-Y, Di P, Li Q-P, et al. Blood coagulation system in patients with chronic kidney disease: a prospective observational study. BMJ Open. 2017;7(5):e014294. doi: 10.1136/bmjopen-2016-014294 PubMed DOI PMC

Acetylsalicylic acid and vorapaxar are less active, while 4-methylcatechol is more active, in type 1 diabetic patients compared to healthy controls